Vamsee Torri, MD

Specializes in Thoracic, Gastrointestinal and Genitourinary Medical Oncology, and Prostate Cancer

Vamsee Torri, MD, FACP, FRCPC, is a board-certified medical oncologist with the Dignity Health – Cancer Institute at St. Joseph’s Hospital and Medical Center. He treats gastrointestinal and genitourinary malignancies.

He specializes in the care of patients with gastrointestinal malignancies affecting the esophagus, stomach, liver, pancreas, gall bladder and genitourinary malignancies affecting the kidneys, bladder, prostate, urinary tract, testicular and penile areas.

Dr. Torri received his medical degree from Jawaharlal Nehru Medical College, India. He completed his residency in Internal Medicine and fellowship in Hematology and Oncology at St. Luke’s-Roosevelt Hospital Center, New York. Subsequently, he worked as a medical oncologist at Saskatchewan Cancer Agency and CancerCare Manitoba, Canada.

In addition to clinical care, he was actively involved in clinical research, developing local practice guidelines, and medical education.  Aligning with the Dignity Health mission, Dr. Torri’s philosophy is to provide individualized, compassionate care, and innovative therapies through clinical trials.

For more information about Dr. Torri or to schedule an appointment at the Dignity Health – Cancer Institute at St. Joseph’s, please call us at (602) 406-8222. Our fax number is 602.406.6242.
  • Prostate cancer
  • Bladder cancer
  • Kidney cancer
  • Testicular cancer
  • Thoracic cancer
  • Urethral cancer
  • Penile cancer
  • American Board of Medical Specialties: Internal Medicine, Hematology, Medical Oncology
  • Royal College of Physicians and Surgeons of Canada: Internal Medicine, Medical Oncology
  • American College of Physicians
  • American Society of Clinical Oncology
  • American Society of Hematology
  • Medical Education: Jawaharlal Nehru Medical College, India
  • Internal Medicine Residency: St. Luke’s Roosevelt Hospital Center, New York
  • Hematology-Oncology Fellowship: St. Luke’s Roosevelt Hospital Center, New York
  • Hotte SJ, Chi KN, Joshua AM, Tu D, Macfarlane RJ, Gregg RW, Ruether JD, Basappa NS, Finch D, Salim M, Winquist EW, Torri V, North S, Kollmannsberger C, Ellard SL, Eigl BJ, Tinker A, Allan AL, Beja K, Annala M, Powers J, Wyatt AW, Seymour L. A Phase II Study of PX-866 in Patients with Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. Clin Genitourin Cancer. 2019 Jun;17(3):201-208.
  • Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C, Kuruvilla S, Keith BD, Torri V, Blais N, Hao D, Korpanty GJ, Goss G, Melosky BL, Mates M, Leighl N, Ayoub JP, Sederias J, Feilotter H, Seymour L, Laurie SA. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. Lung Cancer. 2018 Jun;120:142-148
  • Torri V, Dolata W, Vu K, Dubey A, Brunet B, Tai P. Melanoma. Current Cancer Therapy Reviews, volume 12, issue 3, pages 172-203, year 2016, issn 1573-3947/ 1875-6301
  • Torri V. Chemotherapy and Molecular Therapy in Non-Melanoma Skin Cancer. Current Cancer Therapy Reviews, volume 12, issue 3, pages 166-171, year 2016, issn 1573-3947/ 1875-6301
  • Tai P, Vu K, Torri V, Suderman D, Dubey A. Merkel Cell Carcinoma – Current State and the Future. Current Cancer Therapy Reviews, volume 12, issue 2, pages 79-86, year 2016, issn 1573-3947/ 1875-6301